Back to the directory

SFA Therapeutics

Regulating the immune system to block cancer & autoimmune diseases

Founded
2016
Status
Active
Stage
Early
Team size
4
Location
Philadelphia, PA, USA
Category
Biotech & Drug Discovery
Sector
Therapeutics

About SFA Therapeutics

SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis and NASH. we have a total of 9 drugs in our pipeline and 15 patents.

AI-powered Drug DiscoveryAnti-AgingBiotechBiotechnologyHealth & Wellness

Clinical trials

2 registered trials with this company as lead sponsor, 2022 to 2025.

Phases
Phase 1 (1), Phase 2 (1), Phase 3 (1)
Status
Recruiting (1), Not yet recruiting (1)
Conditions
Psoriasis (PsO), Psoriasis

NCT06863493, NCT05642182

Source: ClinicalTrials.gov.

Company data compiled and maintained by Healthcare Discovery.